Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
NGNE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.41
vs -2.36
Q4.23
N/A
-1.51
vs -0.26
Q1.24
N/A
-1.00
vs NA
Q2.24
N/A
-1.09
vs -0.04
Q3.24
N/A
-1.19
vs -0.41
Q4.24
N/A
-0.99
vs -1.51
Q1.25
N/A
-1.08
vs -1.00
Q2.25
N/A
-1.05
vs -1.09
Q3.25
N/A
-1.25
vs -1.19
Q4.25
N/A
-1.36
vs -0.99
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
925K vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
-925000.00 vs NA
Q1.25
NA
NA vs NA
Q2.25
-100%
NA vs 925K
Return on Equity
QoQ
Q1.23
-17%
-0.17
vs -0.14
Q2.23
+7%
0.07
vs -0.17
Q3.23
-6%
-0.06
vs 0.07
Q4.23
-8%
-0.08
vs -0.06
Q1.24
-10%
-0.10
vs -0.08
Q2.24
-12%
-0.12
vs -0.10
Q3.24
-15%
-0.15
vs -0.12
Q4.24
-6%
-0.06
vs -0.15
Q1.25
-8%
-0.08
vs -0.06
Q2.25
-8%
-0.08
vs -0.08
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
34
34
vs NA
NA
Q1.24
60
60
vs 34
76%
Q2.24
66
66
vs 60
10%
Q3.24
85
85
vs 66
29%
Q4.24
91
91
vs 85
7%
Q1.25
86
86
vs 91
-5%
Q2.25
80
80
vs 86
-7%
businesswire.com
7 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
Quote Panel
Key Metrics
Relative Strength
NGNE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
NASDAQ
Unprofitable
Unprofitable
-1.25 ( -3.96%)
Relative Strenght
80
Volume Buzz
-74%
Earning Acce
Yes
Dist 52w H.
59%Forecast
-50%2026-Revenue
-25%2026-EPS
-50%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
45.00(48.42%)
Number of analyst
1
Last analyst upgrade/downgrade
Craig-Hallum
initialisePrevious: Not converted
2025-06-17
Now: Buy
BMO Capital
initialisePrevious: Not converted
2024-06-26
Now: Outperform